Status:
COMPLETED
Oral Vinorelbine and Cisplatin and Concurrent Radiotherapy After Induction Chemotherapy in Locally Advanced NSCLC.
Lead Sponsor:
University Hospital, Brest
Collaborating Sponsors:
Fabre Clinic
Conditions:
Lung Neoplasm
Eligibility:
All Genders
18-70 years
Phase:
PHASE2
Brief Summary
Our aim is to conducted a multicenter phase II trial of the cisplatin-oral vinorelbine -radiotherapy combination after induction chemotherapy with cisplatin-docetaxel in patient with NSCLC. Oral vinor...
Detailed Description
About one-third of patients with non-small-cell lung cancer (NSCLC) have inoperable, locally advanced stage III disease at diagnosis. The most satisfactory treatment for patients with locally advanced...
Eligibility Criteria
Inclusion
- histologically or cytologically documented inoperable stage IIIA N2 or IIIB NSCLC previously untreated, absence of malignant pleural effusion, performance status (PS) =1 and patient life expectancy of at least 12 weeks.
Exclusion
- metastatic disease, small Cell lung carcinoma, prior chemotherapy, prior radiotherapy, resecable tumor, any instable systemic disease, any other malignancies within 5 years,
Key Trial Info
Start Date :
February 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
June 1 2007
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT00295672
Start Date
February 1 2006
End Date
June 1 2007
Last Update
July 28 2009
Active Locations (6)
Enter a location and click search to find clinical trials sorted by distance.
1
CHU of Brest
Brest, France, 29250
2
CH GAP
Gap, France, 05000
3
CHU de LIMOGES
Limoges, France, 87042
4
Hopital de la Croix Rousse
Lyon, France, 69317